SFCM
RGC icon

Seven Fleet Capital Management’s Regencell Bioscience RGC Stock Holding History

Seven Fleet Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,400
Closed -$92.4K – 133
2025
Q4 		$92.4K Buy
+4,400
New +$71.5K 0.06% 72

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $13.9B AUM 53.47% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Seven Fleet Capital Management's RGC Position: Q1 2026 in Review

Seven Fleet Capital Management sold out of Regencell Bioscience (RGC) in Q1 2026, closing a stake of 4,400 shares — an estimated $92.4K sold.

Seven Fleet Capital Management first reported a position in RGC in Q4 2025 and held it in 1 quarter. The position peaked at $92.4K in Q4 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Seven Fleet Capital Management reported no remaining Regencell Bioscience position as of Q1 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 4,400 Regencell Bioscience shares in Q1 2026, an estimated $92.4K.
  • Seven Fleet Capital Management first reported a position in Regencell Bioscience in Q4 2025 and held it in 1 quarter.
  • Seven Fleet Capital Management's Regencell Bioscience position peaked at $92.4K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.